Peking University Pharmaceutical

Peking University Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of chemical drugs and active pharmaceutical ingredients (APIs). Headquartered in Chongqing, the company focuses on core therapeutic areas including oncology, anti-infectives, cardiovascular diseases, and the central nervous system. It operates large-scale manufacturing facilities that comply with international GMP standards, supplying both finished preparations and bulk drug substances to domestic and global markets. As a publicly traded entity on the Shenzhen Stock Exchange, the company has transitioned through significant restructuring under the Peking University Founder Group and more recently under the stewardship of Ping An Insurance. Its product portfolio includes a wide range of essential medicines, from antibiotics like Cefmetazole to targeted cancer therapies like Gefitinib.